Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148

PHASE3CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

January 23, 2020

Primary Completion Date

March 16, 2023

Study Completion Date

March 16, 2023

Conditions
Irritability Associated With Autism Spectrum Disorder
Interventions
DRUG

Brexpiprazole

Oral tablet; taken once daily

Trial Locations (28)

10036

Research site, New York

10314

Richmond Behavioral Associates, Staten Island

10549

Bioscience Research, Mount Kisco

14618

Finger Lakes Clinical Research, Rochester

32803

APG Research, Orlando

36303

Dothan Behavioral Medicine Clinic, Dothan

37203

Access Clinical Trials, Nashville

44012

Research Site, Avon Lake

48302

Research site, Bloomfield Hills

60612

Autism Assessment, Research, Treatment and Services (AARTS) center, Chicago

63304

Research site, Saint Charles

65211

Thompson Center for Autism and Neurodevelopment, Columbia

68526

Alivation, Lincoln

70629

Research site, Lake Charles

73116

The Holloway Group, Inc, Oklahoma City

75251

Cedar Health Research, Dallas

77381

Family Psychiatry of the Woodlands, The Woodlands

78249

Research site, San Antonio

78289

UT Health San Antonio Long School of Medicine, Department of Psychiatry and Behavioral Sciences, San Antonio

78759

Research site, Austin

85006

Southwest Autism Research and Resource Center, Phoenix

89128

Center for Psychiatry and Behavioral Medicine Inc., Las Vegas

98201

Core Clinical Research, Everett

94143-3132

University of California San Francisco, Nancy Friend Pritzker Psychiatry, San Francisco

02421-3114

The Lurie Center for Autism, Lexington

07103

Rutger's-New Jersey Medical Scholl Clinical Research Unit, Newark

08540

For additional information regarding sites, Princeton

05091

Woodstock Research Center, Woodstock

All Listed Sponsors
collaborator

H. Lundbeck A/S

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT04258839 - Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148 | Biotech Hunter | Biotech Hunter